8 Best Telemedicine Virtual Care for February 2026
Welcome to the Value Sense Blog, your resource for insights on the stock market! At Value Sense, we focus on intrinsic value tools and offer stock ideas with undervalued companies. Dive into our research products and learn more about our unique approach at valuesense.io
Explore diverse stock ideas covering technology, healthcare, and commodities sectors. Our insights are crafted to help investors spot opportunities in undervalued growth stocks, enhancing potential returns. Visit us to see evaluations and in-depth market research.
Market Overview & Selection Criteria
The telemedicine and virtual care sector has shown resilience amid evolving healthcare demands, with companies leveraging digital platforms for accessible services. Value Sense selected these 8 telemedicine stock picks using its proprietary machine learning-driven analysis, focusing on intrinsic value estimates, quality ratings, ROIC, revenue growth, and FCF margins to identify potentially undervalued opportunities in healthcare technology. Criteria emphasize companies trading below intrinsic value, positive cash flows where possible, and strong gross margins indicative of scalable models, drawn exclusively from Value Sense data for educational analysis.
Featured Stock Analysis
Stock #1: Hims & Hers Health, Inc. (HIMS)
| Metric | Value |
|---|---|
| Market Cap | $6,272.1M |
| Quality Rating | 6.8 |
| Intrinsic Value | $24.0 |
| 1Y Return | -20.2% |
| Revenue | $2,211.0M |
| Free Cash Flow | $131.5M |
| Revenue Growth | 78.0% |
| FCF margin | 5.9% |
| Gross margin | 75.0% |
| ROIC | 17.7% |
| Total Debt to Equity | 192.4% |
Investment Thesis
Hims & Hers Health, Inc. (HIMS) stands out in the telemedicine space with a Quality rating of 6.8 and an intrinsic value of $24.0, suggesting significant undervaluation potential for value-focused analysis. The company reports robust Revenue of $2,211.0M and Free Cash Flow of $131.5M, driven by explosive Revenue growth of 78.0%. Strong Gross margin at 75.0% and ROIC of 17.7% highlight operational efficiency in virtual health services, despite a 1Y Return of -20.2% and elevated Total Debt to Equity of 192.4%. FCF margin of 5.9% supports sustainability in a competitive market, positioning HIMS as a growth-oriented pick in Value Sense evaluations.
This analysis reveals a company scaling rapidly in personalized telehealth, with metrics underscoring potential for margin expansion as adoption grows.
Key Catalysts
- Exceptional 78.0% revenue growth signaling strong market demand for virtual care
- High 75.0% gross margin enabling scalability and profitability
- Solid 17.7% ROIC demonstrating efficient capital use
Risk Factors
- High 192.4% total debt to equity raising leverage concerns
- Negative 1Y return of -20.2% amid market volatility
Stock #2: Oscar Health, Inc. (OSCR)
| Metric | Value |
|---|---|
| Market Cap | $3,753.0M |
| Quality Rating | 5.1 |
| Intrinsic Value | $20.1 |
| 1Y Return | -17.1% |
| Revenue | $11.3B |
| Free Cash Flow | $735.6M |
| Revenue Growth | 37.4% |
| FCF margin | 6.5% |
| Gross margin | 21.2% |
| ROIC | 92.4% |
| Total Debt to Equity | 66.8% |
Investment Thesis
Oscar Health, Inc. (OSCR) features a Quality rating of 5.1 and intrinsic value of $20.1, indicating room for appreciation in telemedicine insurance models. With Market Cap at $3,753.0M, Revenue reaches $11.3B and Free Cash Flow $735.6M, fueled by 37.4% Revenue growth. ROIC of 92.4% is a standout, though Gross margin is 21.2% and FCF margin 6.5%, with 1Y Return at -17.1% and Total Debt to Equity 66.8%. Value Sense data points to a high-growth profile in virtual health plans, balancing scale with efficiency.
The metrics suggest OSCR's tech-driven approach could drive further value if growth sustains.
Key Catalysts
- Impressive 92.4% ROIC reflecting superior returns on capital
- 37.4% revenue growth from expanding health insurance via telehealth
- Strong $735.6M free cash flow supporting operations
Risk Factors
- Moderate 66.8% debt to equity level
- Lower 21.2% gross margin vulnerable to cost pressures
Stock #3: Teladoc Health, Inc. (TDOC)
| Metric | Value |
|---|---|
| Market Cap | $959.2M |
| Quality Rating | 5.7 |
| Intrinsic Value | $59.9 |
| 1Y Return | -47.3% |
| Revenue | $2,528.2M |
| Free Cash Flow | $256.6M |
| Revenue Growth | (2.4%) |
| FCF margin | 10.1% |
| Gross margin | 69.8% |
| ROIC | (13.1%) |
| Total Debt to Equity | 74.1% |
Investment Thesis
Teladoc Health, Inc. (TDOC) shows a Quality rating of 5.7 and compelling intrinsic value of $59.9 against a Market Cap of $959.2M, highlighting deep undervaluation in established telemedicine. Revenue is $2,528.2M with Free Cash Flow $256.6M and FCF margin 10.1%, supported by 69.8% Gross margin, though Revenue growth is -2.4% and ROIC -13.1%. 1Y Return of -47.3% and Total Debt to Equity 74.1% reflect challenges, but Value Sense metrics suggest recovery potential through cost discipline.
This positions TDOC as a turnaround candidate in virtual care consolidation.
Key Catalysts
- High 69.8% gross margin for profitability leverage
- Positive $256.6M free cash flow amid restructuring
- Strong 10.1% FCF margin indicating cash generation
Risk Factors
- Negative -2.4% revenue growth signaling stagnation
- -47.3% 1Y return and negative ROIC
Stock #4: GoodRx Holdings, Inc. (GDRX)
| Metric | Value |
|---|---|
| Market Cap | $791.1M |
| Quality Rating | 6.1 |
| Intrinsic Value | $12.3 |
| 1Y Return | -54.1% |
| Revenue | $800.7M |
| Free Cash Flow | $86.6M |
| Revenue Growth | 1.3% |
| FCF margin | 10.8% |
| Gross margin | 91.0% |
| ROIC | 10.8% |
| Total Debt to Equity | 10.2% |
Investment Thesis
GoodRx Holdings, Inc. (GDRX) earns a Quality rating of 6.1 with intrinsic value $12.3 and Market Cap $791.1M, appealing for prescription telehealth analysis. Revenue $800.7M pairs with Free Cash Flow $86.6M and top-tier 91.0% Gross margin, 10.8% FCF margin, and 10.8% ROIC. Modest 1.3% Revenue growth and -54.1% 1Y Return contrast low 10.2% Total Debt to Equity, per Value Sense data, suggesting stability in digital pharmacy services.
GDRX's margins make it a defensive play in volatile healthcare tech.
Key Catalysts
- Exceptional 91.0% gross margin driving efficiency
- Healthy 10.8% FCF margin and ROIC
- Low 10.2% debt to equity for balance sheet strength
Risk Factors
- Sluggish 1.3% revenue growth
- Sharp -54.1% 1Y return
Most investors waste time on the wrong metrics. We've spent 10,000+ hours perfecting our value investing engine to find what actually matters.
Want to see what we'll uncover next - before everyone else does?
Find Hidden Gems First!
Stock #5: Talkspace, Inc. (TALK)
| Metric | Value |
|---|---|
| Market Cap | $659.4M |
| Quality Rating | 6.3 |
| Intrinsic Value | $2.6 |
| 1Y Return | 28.7% |
| Revenue | $266.7M |
| Free Cash Flow | $26.0M |
| Revenue Growth | 47.1% |
| FCF margin | 9.7% |
| Gross margin | 43.6% |
| ROIC | (1.7%) |
| Total Debt to Equity | 0.0% |
Investment Thesis
Talkspace, Inc. (TALK) has a Quality rating of 6.3, intrinsic value $2.6, and Market Cap $659.4M, with positive 28.7% 1Y Return as the outlier. Revenue $266.7M grows 47.1%, yielding Free Cash Flow $26.0M (9.7% margin), though Gross margin 43.6% and ROIC -1.7%. Zero Total Debt to Equity bolsters the profile in mental health teletherapy, via Value Sense insights.
This debt-free status supports growth without dilution risks.
Key Catalysts
- 47.1% revenue growth in mental health virtual care
- Positive 28.7% 1Y return momentum
- 0.0% debt to equity for financial flexibility
Risk Factors
- Negative -1.7% ROIC
- Moderate 43.6% gross margin
Stock #6: LifeMD, Inc. (LFMD)
| Metric | Value |
|---|---|
| Market Cap | $149.8M |
| Quality Rating | 6.5 |
| Intrinsic Value | $2.2 |
| 1Y Return | -43.6% |
| Revenue | $225.1M |
| Free Cash Flow | $19.7M |
| Revenue Growth | 25.1% |
| FCF margin | 8.8% |
| Gross margin | 97.5% |
| ROIC | 162.7% |
| Total Debt to Equity | 193.7% |
Investment Thesis
LifeMD, Inc. (LFMD) scores a high Quality rating 6.5, intrinsic value $2.2, and small Market Cap $149.8M. Revenue $225.1M shows 25.1% growth, Free Cash Flow $19.7M (8.8% margin), elite 97.5% Gross margin, and 162.7% ROIC, offset by -43.6% 1Y Return and 193.7% Total Debt to Equity. Value Sense data flags it as a high-ROIC microcap in personalized telehealth.
Exceptional margins could fuel upside if debt managed.
Key Catalysts
- Sky-high 162.7% ROIC and 97.5% gross margin
- 25.1% revenue growth trajectory
- Positive free cash flow generation
Risk Factors
- Elevated 193.7% debt to equity
- -43.6% 1Y return volatility
Stock #7: American Well Corporation (AMWL)
| Metric | Value |
|---|---|
| Market Cap | $72.2M |
| Quality Rating | 4.0 |
| Intrinsic Value | $86.2 |
| 1Y Return | -60.9% |
| Revenue | $208.7M |
| Free Cash Flow | ($64.5M) |
| Revenue Growth | (17.8%) |
| FCF margin | (30.9%) |
| Gross margin | 39.6% |
| ROIC | (90.2%) |
| Total Debt to Equity | 2.0% |
Investment Thesis
American Well Corporation (AMWL) has a lower Quality rating 4.0 but striking intrinsic value $86.2 versus Market Cap $72.2M, implying massive undervaluation. Revenue $208.7M declines -17.8%, with negative Free Cash Flow ($64.5M, -30.9% margin) and ROIC -90.2%, Gross margin 39.6%, -60.9% 1Y Return, low 2.0% Total Debt to Equity. Value Sense highlights platform potential in enterprise telehealth despite challenges.
A speculative deep-value play per metrics.
Key Catalysts
- Vast intrinsic value gap at $86.2
- Low 2.0% debt to equity
- Established platform for virtual care partnerships
Risk Factors
- Negative revenue growth and free cash flow
- Poor -90.2% ROIC and -60.9% 1Y return
Stock #8: EUDA Health Holdings Limited (EUDA)
| Metric | Value |
|---|---|
| Market Cap | $48.2M |
| Quality Rating | 4.9 |
| Intrinsic Value | $2.7 |
| 1Y Return | -65.4% |
| Revenue | $5,160.3K |
| Free Cash Flow | ($2,110.4K) |
| Revenue Growth | 170.4% |
| FCF margin | (40.9%) |
| Gross margin | 22.4% |
| ROIC | (262.9%) |
| Total Debt to Equity | (61.3%) |
Investment Thesis
EUDA Health Holdings Limited (EUDA) rates 4.9 in Quality, with intrinsic value $2.7 and tiny Market Cap $48.2M. Revenue $5,160.3K surges 170.4%, but Free Cash Flow is negative ($2,110.4K, -40.9% margin), Gross margin 22.4%, ROIC -262.9%, -65.4% 1Y Return, and negative Total Debt to Equity -61.3%. Value Sense data shows hyper-growth in niche virtual care, early-stage risks high.
High growth but profitability hurdles.
Key Catalysts
- Explosive 170.4% revenue growth
- Intrinsic value alignment for small-cap watchers
Risk Factors
- Deeply negative ROIC and free cash flow
- -65.4% 1Y return and negative equity
Portfolio Diversification Insights
These 8 telemedicine stocks cluster in healthcare technology, offering sector allocation across virtual primary care (HIMS, OSCR), established platforms (TDOC, AMWL), mental health (TALK), pharmacy (GDRX), and microcaps (LFMD, EUDA). Larger caps like HIMS $6.3B and OSCR $3.8B provide stability with high growth/ROIC, while small caps like AMWL and EUDA add high-upside volatility. Diversifying 40% large/mid-cap, 30% established, 30% growth/micro balances risk—strong margins (e.g., GDRX 91%, LFMD 97.5%) complement variable ROIC/FCF, reducing telemedicine sector concentration.
Market Timing & Entry Strategies
Consider positions during healthcare tech dips or post-earnings clarity, targeting entries below intrinsic values (e.g., TDOC at $59.9, AMWL $86.2). Ladder buys on revenue growth confirmations (HIMS 78%, EUDA 170%), monitoring FCF trends and debt levels. Use Value Sense screeners for ROIC >15% or undervaluation >20%; scale in over 3-6 months for volatility.
Explore More Investment Opportunities
For investors seeking undervalued companies with high fundamental quality, our analytics team provides curated stock lists:
📌 50 Undervalued Stocks (Best overall value plays for 2025)
📌 50 Undervalued Dividend Stocks (For income-focused investors)
📌 50 Undervalued Growth Stocks (High-growth potential with strong fundamentals)
🔍 Check out these stocks on the Value Sense platform for free!
More Articles You Might Like
- Nelson Peltz - Trian Fund Management Portfolio Q3'2025: Top Holdings & Recent Changes
- Principles for Dealing with the Changing World Order by Ray Dalio
- The Ascent of Money by Niall Ferguson
- Principles for Navigating Big Debt Crises by Ray Dalio
- Influence: The Psychology of Persuasion by Robert B. Cialdini Ph.D.
FAQ Section
How were these stocks selected?
These telemedicine stock picks were chosen using Value Sense's automated fundamental analysis, prioritizing intrinsic value upside, quality ratings above 4.0, revenue growth, and margins from the provided data.
What's the best stock from this list?
HIMS leads with highest Quality rating 6.8, 78% growth, and 17.7% ROIC, though all offer unique angles like OSCR's 92.4% ROIC for comparative educational review.
Should I buy all these stocks or diversify?
Diversification across market caps and sub-sectors (e.g., 40% large-cap like HIMS/OSCR) mitigates risks; analyze via Value Sense tools rather than concentrating.
What are the biggest risks with these picks?
Key concerns include high debt (HIMS 192.4%, LFMD 193.7%), negative growth/FCF (TDOC, AMWL, EUDA), and 1Y losses averaging -40%, per data.
When is the best time to invest in these stocks?
Optimal timing aligns with dips below intrinsic values, positive FCF inflection, or sector catalysts like telehealth policy shifts; use backtested screeners for entry signals.